Hypertensive nephropathy primary prevention

Revision as of 21:04, 18 June 2020 by NNikravangolsefid (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Hypertensive nephropathy Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Differentiating Hypertensive Nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Abdominal X Ray

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypertensive nephropathy primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypertensive nephropathy primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypertensive nephropathy primary prevention

CDC on Hypertensive nephropathy primary prevention

Hypertensive nephropathy primary prevention in the news

Blogs on Hypertensive nephropathy primary prevention

Directions to Hospitals Treating Hypertensive nephropathy

Risk calculators and risk factors for Hypertensive nephropathy primary prevention

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nasrin Nikravangolsefid, MD-MPH [2]

Overview

Effective measures for primary prevention of Hypertensive nephropathy include detecting and controlling hypertension at the initial stages.

Primary Prevention

  • Effective measures for reducing blood pressure as primary prevention of Hypertensive nephropathy include:[1]
    • Lifestyle modification
      • Weight reduction
      • DASH diet
      • sodium intake restriction
      • Increase physical activity
    • Pharmacological therapy for hypertension
      • Among medications for controlling BP, Renin-angiotensin-aldosterone (RAAS) blockers such as ACEI or ARB play a significant role in preventing progression to ESRD by reducing proteinuria in hypertensive patients.
        • According to 2017 guidelines, the goal of BP is < 130/80 mmHg for patients with hypertension and CKD regardless of proteinuria.[2]



References

  1. Hart, Peter D; Bakris, George L (2010). "Hypertensive nephropathy: prevention and treatment recommendations". Expert Opinion on Pharmacotherapy. 11 (16): 2675–2686. doi:10.1517/14656566.2010.485612. ISSN 1465-6566.
  2. Whelton, Paul K.; Carey, Robert M.; Aronow, Wilbert S.; Casey, Donald E.; Collins, Karen J.; Dennison Himmelfarb, Cheryl; DePalma, Sondra M.; Gidding, Samuel; Jamerson, Kenneth A.; Jones, Daniel W.; MacLaughlin, Eric J.; Muntner, Paul; Ovbiagele, Bruce; Smith, Sidney C.; Spencer, Crystal C.; Stafford, Randall S.; Taler, Sandra J.; Thomas, Randal J.; Williams, Kim A.; Williamson, Jeff D.; Wright, Jackson T. (2018). "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults". Journal of the American College of Cardiology. 71 (19): e127–e248. doi:10.1016/j.jacc.2017.11.006. ISSN 0735-1097.

Template:WH Template:WS